name: Cystourethroscopy with insertion of temporary device for ischemic remodeling of bladder neck


name: Cystourethroscopy with insertion of temporary device for ischemic remodeling of bladder neck and prostate


name: Cystourethroscopy with insertion of temporary device for ischemic remodeling of prostate


name: Cystourethroscopy with insertion of temporary device for pressure necrosis of bladder neck


name: Cystourethroscopy with insertion of temporary device for pressure necrosis of bladder neck and prostate


name: Cystourethroscopy with insertion of temporary device for pressure necrosis of prostate


name: Catheterization with removal of temporary device for ischemic remodeling (ie, pressure necrosis) of bladder neck and prostate


name: Removal of temporary device for pressure necrosis of bladder neck and prostate using catheterization


name: Catheterization with removal of temporary device for ischemic remodeling of bladder neck


name: Catheterization with removal of temporary device for ischemic remodeling of bladder neck and prostate


name: Catheterization with removal of temporary device for ischemic remodeling of prostate


name: Catheterization with removal of temporary device for pressure necrosis of bladder neck


name: Catheterization with removal of temporary device for pressure necrosis of bladder neck and prostate


name: Catheterization with removal of temporary device for pressure necrosis of prostate


name: Ablation of prostate tissue, transurethral, using thermal ultrasound, including magnetic resonance imaging guidance for, and monitoring of, tissue ablation


name: Destruction of prostate tissue through urethra using heat ultrasound with MRI guidance


name: Transurethral ablation of prostate tissue using thermal ultrasound


name: Transurethral ablation of prostate tissue using thermal ultrasound, with magnetic resonance imaging guidance


name: Ablation of prostate tissue, transurethral, using thermal ultrasound, including magnetic resonance imaging guidance for, and monitoring of, tissue ablation; with insertion of transurethral ultrasound transducer for delivery of thermal ultrasound, including suprapubic tube placement and placement of an endorectal cooling device, when performed


name: Insertion of ultrasound transducer through urethra for delivery of heat ultrasound for destruction of prostate tissue using MRI guidance


name: Transurethral ablation of prostate tissue using thermal ultrasound, with insertion of transurethral ultrasound delivery of thermal ultrasound


name: Transurethral ablation of prostate tissue using thermal ultrasound, with insertion of transurethral ultrasound delivery of thermal ultrasound, with suprapubic tube placement and placement of an endorectal cooling device


name: Transurethral ablation of prostate tissue using thermal ultrasound, with magnetic resonance imaging guidance, with insertion of transurethral ultrasound delivery of thermal ultrasound


name: Transurethral ablation of prostate tissue using thermal ultrasound, with magnetic resonance imaging guidance, with insertion of transurethral ultrasound delivery of thermal ultrasound, with suprapubic tube placement and placement of an endorectal cooling device


name: Ablation of 1 or more thyroid nodule(s), one lobe or the isthmus, percutaneous, including imaging guidance, radiofrequency


name: Destruction using heat of one or more nodules on one thyroid lobe


name: Percutaneous radiofrequency ablation of thyroid nodule from one thyroid lobe


name: Percutaneous radiofrequency ablation of thyroid nodule from one thyroid lobe, with imaging guidance


name: Percutaneous radiofrequency ablation of thyroid nodule from thyroid isthmus


name: Percutaneous radiofrequency ablation of thyroid nodule from thyroid isthmus, with imaging guidance


name: Ablation of 1 or more thyroid nodule(s), additional lobe, percutaneous, including imaging guidance, radiofrequency (List separately in addition to code for primary procedure)


name: Destruction using heat of one or more nodules on additional thyroid lobe


name: Percutaneous radiofrequency ablation of thyroid nodule, additional lobe


name: Percutaneous radiofrequency ablation of thyroid nodule, additional lobe, with imaging guidance


name: Magnetic resonance image guided high intensity focused ultrasound (MRgFUS), stereotactic ablation of target, intracranial, including stereotactic navigation and frame placement, when performed


name: MRI guided high intensity focused ultrasound, computer-assisted destruction of intracranial tissue


name: Intracranial stereotactic ablation of target using magnetic resonance image guided high intensity focused ultrasound (MRgFUS)


name: Intracranial stereotactic ablation of target using magnetic resonance image guided high intensity focused ultrasound (MRgFUS), with stereotactic navigation and frame placement


name: thoracic fascial plane block, unilateral


name: Thoracic fascial plane block, unilateral; by injection(s), including imaging guidance, when performed


name: Unilateral thoracic fascial plane block by injection


name: Unilateral thoracic fascial plane block by injection, with imaging guidance


name: Thoracic fascial plane block, unilateral; by continuous infusion(s), including imaging guidance, when performed


name: Unilateral thoracic fascial plane block by continuous infusion


name: Unilateral thoracic fascial plane block by continuous infusion, with imaging guidance


name: Thoracic fascial plane block, bilateral; by injection(s), including imaging guidance, when performed


name: Bilateral thoracic fascial plane block by injection


name: Bilateral thoracic fascial plane block by injection, with imaging guidance


name: Thoracic fascial plane block, bilateral; by continuous infusion(s), including imaging guidance, when performed


name: Bilateral thoracic fascial plane block by infusion(s)


name: Bilateral thoracic fascial plane block by continuous infusion


name: Bilateral thoracic fascial plane block by continuous infusion, with imaging guidance


name: lower extremity fascial plane block, unilateral


name: Lower extremity fascial plane block, unilateral; by injection(s), including imaging guidance, when performed


name: Unilateral lower extremity fascial plane block by injection


name: Unilateral lower extremity fascial plane block by injection, with imaging guidance


name: Lower extremity fascial plane block, unilateral; by continuous infusion(s), including imaging guidance, when performed


name: Unilateral lower extremity fascial plane block by infusion(s)


name: Unilateral lower extremity fascial plane block by continuous infusion


name: Unilateral lower extremity fascial plane block by continuous infusion, with imaging guidance


name: Implantation of iris prosthesis, including suture fixation and repair or removal of iris, when performed


name: Implantation of iris prosthesis with suture fixation


name: Implantation of iris prosthesis with suture fixation and removal of iris


name: Implantation of iris prosthesis with suture fixation and repair of iris


name: Magnetic Resonance Safety Implant/Foreign Body Procedures


name: MR safety implant and/or foreign body assessment by trained clinical staff, including identification and verification of implant components from appropriate sources (eg, surgical reports, imaging reports, medical device databases, device vendors, review of prior imaging), analyzing current MR conditional status of individual components and systems, and consulting published professional guidance with written report


name: MR safety implant and/or foreign body assessment by trained clinical staff, including identification and verification of implant components from appropriate sources (eg, surgical reports, imaging reports, medical device databases, device vendors, review of prior imaging), analyzing current MR conditional status of individual components and systems, and consulting published professional guidance with written report; initial 15 minutes


name: Assessment by trained clinical staff of implant and/or foreign body for MR safety, including identification and verification of implant components from appropriate sources, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance with written report, initial 15 minutes


name: MR foreign body assessment by trained clinical staff, with identification and verification of implant components from medical device databases, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, initial 15 minutes


name: MR safety foreign body assessment by trained clinical staff, with identification and verification of implant components from device vendors, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, initial 15 minutes


name: MR safety foreign body assessment by trained clinical staff, with identification and verification of implant components from imaging reports, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, initial 15 minutes


name: MR safety foreign body assessment by trained clinical staff, with identification and verification of implant components from review of prior imaging, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, initial 15 minutes


name: MR safety foreign body assessment by trained clinical staff, with identification and verification of implant components from surgical reports, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, initial 15 minutes


name: MR safety implant and foreign body assessment by trained clinical staff, with identification and verification of implant components from device vendors, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, initial 15 minutes


name: MR safety implant and foreign body assessment by trained clinical staff, with identification and verification of implant components from imaging reports, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, initial 15 minutes


name: MR safety implant and foreign body assessment by trained clinical staff, with identification and verification of implant components from medical device databases, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, initial 15 minutes


name: MR safety implant and foreign body assessment by trained clinical staff, with identification and verification of implant components from review of prior imaging, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, initial 15 minutes


name: MR safety implant and foreign body assessment by trained clinical staff, with identification and verification of implant components from surgical reports, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, initial 15 minutes


name: MR safety implant assessment by trained clinical staff, with identification and verification of implant components from device vendors, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, initial 15 minutes


name: MR safety implant assessment by trained clinical staff, with identification and verification of implant components from imaging reports, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, initial 15 minutes


name: MR safety implant assessment by trained clinical staff, with identification and verification of implant components from medical device databases, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, initial 15 minutes


name: MR safety implant assessment by trained clinical staff, with identification and verification of implant components from review of prior imaging, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, initial 15 minutes


name: MR safety implant assessment by trained clinical staff, with identification and verification of implant components from surgical reports, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, initial 15 minutes


name: MR safety implant and/or foreign body assessment by trained clinical staff, including identification and verification of implant components from appropriate sources (eg, surgical reports, imaging reports, medical device databases, device vendors, review of prior imaging), analyzing current MR conditional status of individual components and systems, and consulting published professional guidance with written report; each additional 30 minutes (List separately in addition to code for primary procedure)


name: Assessment by trained clinical staff of implant and/or foreign body for MR safety, including identification and verification of implant components from appropriate sources, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance with written report, each additional 30 minutes


name: MR foreign body assessment by trained clinical staff, with identification and verification of implant components from medical device databases, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, each additional 30 minutes


name: MR safety foreign body assessment by trained clinical staff, with identification and verification of implant components from device vendors, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, each additional 30 minutes


name: MR safety foreign body assessment by trained clinical staff, with identification and verification of implant components from imaging reports, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, each additional 30 minutes


name: MR safety foreign body assessment by trained clinical staff, with identification and verification of implant components from review of prior imaging, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, each additional 30 minutes


name: MR safety foreign body assessment by trained clinical staff, with identification and verification of implant components from surgical reports, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, each additional 30 minutes


name: MR safety implant and foreign body assessment by trained clinical staff, with identification and verification of implant components from device vendors, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, each additional 30 minutes


name: MR safety implant and foreign body assessment by trained clinical staff, with identification and verification of implant components from imaging reports, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, each additional 30 minutes


name: MR safety implant and foreign body assessment by trained clinical staff, with identification and verification of implant components from medical device databases, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, each additional 30 minutes


name: MR safety implant and foreign body assessment by trained clinical staff, with identification and verification of implant components from review of prior imaging, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, each additional 30 minutes


name: MR safety implant and foreign body assessment by trained clinical staff, with identification and verification of implant components from surgical reports, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, each additional 30 minutes


name: MR safety implant assessment by trained clinical staff, with identification and verification of implant components from device vendors, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, each additional 30 minutes


name: MR safety implant assessment by trained clinical staff, with identification and verification of implant components from imaging reports, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, each additional 30 minutes


name: MR safety implant assessment by trained clinical staff, with identification and verification of implant components from medical device databases, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, each additional 30 minutes


name: MR safety implant assessment by trained clinical staff, with identification and verification of implant components from review of prior imaging, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, each additional 30 minutes


name: MR safety implant assessment by trained clinical staff, with identification and verification of implant components from surgical reports, analyzing current MR conditional status of individual components and systems, and consulting published professional guidance, with written report, each additional 30 minutes


name: MR safety determination by a physician or other qualified health care professional responsible for the safety of the MR procedure, including review of implant MR conditions for indicated MR examination, analysis of risk vs clinical benefit of performing MR examination, and determination of MR equipment, accessory equipment, and expertise required to perform examination, with written report


name: MR safety determination by a physician responsible for the safety of the MR procedure, with review of implant MR conditions for indicated MR examination, analysis of risk vs clinical benefit of performing MR examination, and determination of MR equipment, accessory equipment, and expertise required to perform examination, with written report


name: MR safety determination by a qualified health care professional responsible for the safety of the MR procedure, with review of implant MR conditions for indicated MR examination, analysis of risk vs clinical benefit of performing MR examination, and determination of MR equipment, accessory equipment, and expertise required to perform examination, with written report


name: MR safety medical physics examination customization, planning and performance monitoring by medical physicist or MR safety expert, with review and analysis by physician or other qualified health care professional to prioritize and select views and imaging sequences, to tailor MR acquisition specific to restrictive requirements or artifacts associated with MR conditional implants or to mitigate risk of non-conditional implants or foreign bodies, with written report


name: MR safety medical physics examination customization, planning and performance monitoring by a MR safety expert, with review and analysis by a physician to mitigate risk of non-conditional implants or foreign bodies, with written report


name: MR safety medical physics examination customization, planning and performance monitoring by a MR safety expert, with review and analysis by a physician to tailor MR acquisition specific to restrictive requirements or artifacts associated with MR conditional implants, with written report


name: MR safety medical physics examination customization, planning and performance monitoring by a MR safety expert, with review and analysis by a qualified healthcare professional to mitigate risk of non-conditional implants or foreign bodies, with written report


name: MR safety medical physics examination customization, planning and performance monitoring by a MR safety expert, with review and analysis by a qualified healthcare professional to prioritize and select views and imaging sequences, with written report


name: MR safety medical physics examination customization, planning and performance monitoring by a MR safety expert, with review and analysis by a qualified healthcare professional to tailor MR acquisition specific to restrictive requirements or artifacts associated with MR conditional implants, with written report


name: MR safety medical physics examination customization, planning and performance monitoring by a MR safety expert, with review and analysis by physician to prioritize and select views and imaging sequences, with written report


name: MR safety medical physics examination customization, planning and performance monitoring by medical physicist, with review and analysis by a physician to mitigate risk of non-conditional implants or foreign bodies, with written report


name: MR safety medical physics examination customization, planning and performance monitoring by medical physicist, with review and analysis by a physician to tailor MR acquisition specific to restrictive requirements or artifacts associated with MR conditional implants, with written report


name: MR safety medical physics examination customization, planning and performance monitoring by medical physicist, with review and analysis by a qualified healthcare professional to mitigate risk of non-conditional implants or foreign bodies, with written report


name: MR safety medical physics examination customization, planning and performance monitoring by medical physicist, with review and analysis by a qualified healthcare professional to prioritize and select views and imaging sequences, with written report


name: MR safety medical physics examination customization, planning and performance monitoring by medical physicist, with review and analysis by a qualified healthcare professional to tailor MR acquisition specific to restrictive requirements or artifacts associated with MR conditional implants, with written report


name: MR safety medical physics examination customization, planning and performance monitoring by medical physicist, with review and analysis by physician to prioritize and select views and imaging sequences, with written report


name: MR safety implant electronics preparation under supervision of physician or other qualified health care professional, including MR-specific programming of pulse generator and/or transmitter to verify device integrity, protection of device internal circuitry from MR electromagnetic fields, and protection of patient from risks of unintended stimulation or heating while in the MR room, with written report


name: Preparation under supervision of physician or other qualified health care professional of electronics for MR safety, including MR-specific programming of pulse generator and/or transmitter to verify device integrity, protection of device internal circuitry from MR electromagnetic fields, and protection of patient from risks of unintended stimulation or heating while in the MR room, with written report


name: MR safety implant electronics preparation under supervision of physician, including MR-specific programming of pulse generator and/or transmitter to verify device integrity, protection of device internal circuitry from MR electromagnetic fields, and protection of patient from risks of unintended stimulation or heating while in the MR room, with written report


name: MR safety implant electronics preparation under supervision qualified health care professional, including MR-specific programming of pulse generator and/or transmitter to verify device integrity, protection of device internal circuitry from MR electromagnetic fields, and protection of patient from risks of unintended stimulation or heating while in the MR room, with written report


name: MR safety implant positioning and/or immobilization under supervision of physician or other qualified health care professional, including application of physical protections to secure implanted medical device from MR-induced translational or vibrational forces, magnetically induced functional changes, and/or prevention of radiofrequency burns from inadvertent tissue contact while in the MR room, with written report


name: MR safety implant positioning and/or immobilization under supervision of physician, with application of physical protections to secure implanted medical device from MR-induced translational or vibrational forces, magnetically induced functional changes, and/or prevention of radiofrequency burns from inadvertent tissue contact while in the MR room, with written report


name: MR safety implant positioning and/or immobilization under supervision of qualified healthcare professional, with application of physical protections to secure implanted medical device from MR-induced translational or vibrational forces, magnetically induced functional changes, and/or prevention of radiofrequency burns from inadvertent tissue contact while in the MR room, with written report


name: Delivery of radiation therapy per dose to 1 or more lesions not to exceed 5 doses


name: Cytogenomic (genome-wide) analysis, hematologic malignancy, structural variants and copy number variants, optical genome mapping (OGM)


name: Optical genome mapping for hematologic malignancy


name: Test for detecting genes associated with inherited breast cancer-related disorders, genomic sequence analysis, at least 5 genes


name: Test for detecting genes associated with inherited colon cancer-related disorders, genomic sequence analysis, at least 5 genes


name: Test for detecting genes associated with inherited neuroendocrine tumor-related disorders, genomic sequence analysis, at least 5 genes


name: Infectious disease, bacterial vaginosis and vaginitis, real-time PCR amplification of DNA markers for Atopobium vaginae, Atopobium species, Megasphaera type 1, and Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), utilizing vaginal-fluid specimens, algorithm reported as positive or negative for high likelihood of bacterial vaginosis, includes separate detection of Trichomonas vaginalis and Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata/Candida krusei, when reported


name: Test for detection of bacteria causing vaginosis and vaginitis


name: Detection of bacterial vaginosis and vaginitis by real-time PCR amplification of DNA markers for Atopobium vaginae, Atopobium species, and Megasphera type 1, Bacterial Vaginosis-Associated Bacteria 2 (BVAB-2), in vaginal fluid specimen, algorithm reported as positive or negative for high likelihood of bacterial vaginosis, with separate detection of Trichomonas vaginalis and Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata/Candida krusei


name: Transplantation medicine (allograft rejection, kidney), mRNA, gene expression profiling by quantitative polymerase chain reaction (qPCR) of 139 genes, utilizing whole blood, algorithm reported as a binary categorization as transplant excellence, which indicates immune quiescence, or not transplant excellence, indicating subclinical rejection


name: Test for detecting 139 genes associated with kidney transplant rejection


name: Kidney allograft rejection mRNA gene expression profiling by quantitative polymerase chain reaction (qPCR) of 139 genes, in whole blood, algorithm reported as a binary categorization as transplant excellence, which indicates immune quiescence, or not transplant excellence, indicating subclinical rejection


name: Tau, phosphorylated (eg, pTau 181, pTau 217), each


name: Streptococcus pneumoniae antibody (IgG), serotypes, multiplex immunoassay, quantitative


name: Test for streptococcus pneumonia antibody


name: Infectious agent detection by nucleic acid (DNA or RNA); Helicobacter pylori (H. pylori), clarithromycin resistance, amplified probe technique


name: Detection test by nucleic acid for helicobacter pylori clarithromycin resistance, amplified probe technique


name: Detection of helicobacter pylori (H. pylori) for clarithromycin resistance by amplified DNA probe technique


name: Detection of helicobacter pylori (H. pylori) for clarithromycin resistance by amplified RNA probe technique


name: Human Papillomavirus (HPV) detection by DNA for high-risk types, pooled result


name: Human Papillomavirus (HPV) detection by RNA for high-risk types, pooled result


name: Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), separately reported high-risk types (eg, 16, 18, 31, 45, 51, 52) and high-risk pooled result(s)


name: Detection test by nucleic acid for Human Papillomavirus (HPV), separately reported high-risk types


name: Human Papillomavirus (HPV) detection by DNA for high-risk types, high-risk pooled result(s)


name: Human Papillomavirus (HPV) detection by DNA for high-risk types, separately reported high-risk types


name: Human Papillomavirus (HPV) detection by DNA for high-risk types, separately reported high-risk types and high-risk pooled result(s)


name: Human Papillomavirus (HPV) detection by RNA for high-risk types, high-risk pooled result(s)


name: Human Papillomavirus (HPV) detection by RNA for high-risk types, separately reported high-risk types


name: Human Papillomavirus (HPV) detection by RNA for high-risk types, separately reported high-risk types and high-risk pooled result(s)


name: Infectious agent detection by nucleic acid (DNA or RNA); Mycobacterium tuberculosis, rifampin resistance, amplified probe technique


name: Detection test by nucleic acid for mycobacterium tuberculosis rifampin resistance


name: Detection of Mycobacterium tuberculosis for rifampin resistance by amplified DNA probe technique


name: Detection of Mycobacterium tuberculosis for rifampin resistance by amplified RNA probe technique


name: Infectious agent detection by nucleic acid (DNA or RNA); Pneumocystis jirovecii, amplified probe technique


name: Detection test by nucleic acid for pneumocystis jirovecii


name: Detection of Pneumocystis jirovecii by amplified DNA probe technique


name: Detection of Pneumocystis jirovecii by amplified RNA probe technique


name: Spheroid cell culture in 3D microenvironment with 12 drug panel, with brain metastasis-response prediction for each drug


name: Spheroid cell culture in 3D microenvironment with 12 drug panel, with brain-response prediction for each drug


name: Oncology (oropharyngeal or anal), evaluation of 17 DNA biomarkers using droplet digital PCR (ddPCR), cell-free DNA, algorithm reported as a prognostic risk score for cancer recurrence


name: Evaluation of 17 DNA biomarkers reported as a risk score for tonsil or anal cancer recurrence


name: Evaluation of 18 genes by mRNA gene expression profiling in first-catch urine, algorithm reported as percentage of likelihood of detecting clinically significant prostate cancer


name: mRNA expression profiling of 6 single-nucleotide polymorphisms (SNPs) in urine reported as s risk score for urothelial carcinoma


name: Screening test for 8 RNA markers and blood in stool reported as positive or negative for colorectal cancer risk


name: Analysis of DNA biomarker response to anti-cancer therapy reported as a change from baseline


name: Analysis of DNA biomarker response to anti-cancer therapy using cell-free circulating DNA, biomarker comparison to a previous baseline pre-treatment cell-free circulating DNA analysis using next-generation sequencing, algorithm reported as a quantitative change from baseline, including specific alterations


name: Genomic analysis panel of 26 genes from cheek swab, report including metabolizer status and risk of drug toxicity by psychiatric condition


name: Genomic analysis panel, including variant analysis of 26 genes, in buccal swab, report including metabolizer status and risk of drug toxicity by condition


name: Exosome-based analysis of 53 small non coding RNAs (sncRNAs) in urine, reported as risk for prostate cancer


name: Genome rapid sequence analysis, each comparator gene (eg, parents, siblings) for unexplained constitutional or heritable disorder or syndrome


name: Ultra-rapid genome sequence analysis for unexplained constitutional or heritable disorder or syndrome


name: Targeted hybrid-capture genomic sequence analysis panel, circulating tumor DNA (ctDNA) analysis of 56 or more genes in breast cancer


name: Testing for Human papillomavirus (HPV) from throat swab


name: Glycine receptor alpha1 IgG live cell-binding assay in serum or cerebral spinal fluid (CSF)


name: Qualitative live cell-binding assay (LCBA) for glycine receptor alpha1 IgG in cerebrospinal fluid (CSF)


name: Qualitative live cell-binding assay (LCBA) for glycine receptor alpha1 IgG in serum


name: Kelch-like protein 11 (KLHL11) antibody cell-binding assay in serum or cerebrospinal fluid (CSF)


name: Qualitative cell-binding assay for kelch-like protein 11 (KLHL11) antibody in cerebrospinal fluid (CSF)


name: Qualitative cell-binding assay for kelch-like protein 11 (KLHL11) antibody in serum


name: Testing for 5 DNA regulatory markers by quantitative PCR in whole blood, reported as likelihood of prostate cancer


name: Genomic analysis panel of 25 genes to evaluation drug metabolism


name: Chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), reported based on cytotoxicity percentage observed for a minimum of 14 drugs or drug combinations


name: Plasma analysis of 388 proteins reported as clinical benefit from immune checkpoint inhibitor therapy in lung cancer


name: Variant analysis of gene-drug interactions of 33 genes from cheek swab to evaluate for adverse drug reactions and drug response


name: Cardiology (coronary heart disease [CHD]), DNA, analysis of 5 single-nucleotide polymorphisms (SNPs) (rs11716050 [LOC105376934], rs6560711 [WDR37], rs3735222 [SCIN/LOC107986769], rs6820447 [intergenic], and rs9638144 [ESYT2]) and 3 DNA methylation markers (cg00300879 [transcription start site {TSS200} of CNKSR1], cg09552548 [intergenic], and cg14789911 [body of SPATC1L]), qPCR and digital PCR, whole blood, algorithm reported as a 4-tiered risk score for a 3-year risk of symptomatic CHD


name: qPCR and digital PCR DNA analysis of 5 single-nucleotide polymorphisms (SNPs) and 3 DNA methylation markers in whole blood, reported as a 4-tiered risk score for a 3-year risk of symptomatic coronary heart disease (CHD)


name: Cardiology (coronary heart disease [CHD]), DNA, analysis of 10 single-nucleotide polymorphisms (SNPs) (rs710987 [LINC010019], rs1333048 [CDKN2B-AS1], rs12129789 [KCND3], rs942317 [KTN1-AS1], rs1441433 [PPP3CA], rs2869675 [PREX1], rs4639796 [ZBTB41], rs4376434 [LINC00972], rs12714414 [TMEM18], and rs7585056 [TMEM18]) and 6 DNA methylation markers (cg03725309 [SARS1], cg12586707 [CXCL1], cg04988978 [MPO], cg17901584 [DHCR24-DT], cg21161138 [AHRR], and cg12655112 [EHD4]), qPCR and digital PCR, whole blood, algorithm reported as detected or not detected for CHD


name: qPCR and digital PCR DNA, analysis of 10 single-nucleotide polymorphisms (SNPs) and 6 DNA methylation markers in whole blood, reported as detected or not detected for evaluation of coronary heart disease (CHD)


name: Infectious disease (bacterial, fungal, or viral infection), semiquantitative biomechanical assessment (via deformability cytometry), whole blood, with algorithmic analysis and result reported as an index


name: Semiquantitative biomechanical assessment (via deformability cytometry), in whole blood, with algorithmic analysis and result reported as an index for bacterial infection


name: Semiquantitative biomechanical assessment (via deformability cytometry), in whole blood, with algorithmic analysis and result reported as an index for fungal infection


name: Semiquantitative biomechanical assessment (via deformability cytometry), in whole blood, with algorithmic analysis and result reported as an index for viral infection


name: Infectious disease (respiratory infection), Myxovirus resistance protein A (MxA) and C-reactive protein (CRP), fingerstick whole blood specimen, each biomarker reported as present or absent


name: Test for Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) in fingerstick whole blood specimen, each biomarker reported as present or absent


name: Neurofilament light chain (NfL), ultra-sensitive immunoassay, serum or cerebrospinal fluid


name: Ultra-sensitive immunoassay for neurofilament light chain (Nfl) in cerebrospinal fluid


name: Ultra-sensitive immunoassay for neurofilament light chain (Nfl) in serum


name: Oncology (solid organ neoplasia), targeted genomic sequence analysis panel of 361 genes, interrogation for gene fusions, translocations, or other rearrangements, using DNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue, report of clinically significant variant(s)


name: β-amyloid (Abeta42) and phospho tau (181P) (pTau181), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology


name: Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 10 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic risk score for current disease activity


name: Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 11 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic prognostic risk score for developing a clinical flare


name: Qualitative, next-generation DNA sequencing detection of single-nucleotide variants and deletions in EGFR and KRAS genes in formalin-fixed paraffin-embedded (FFPE) solid tumor samples, reported as presence or absence of targeted mutation(s), with recommended therapeutic options in colon cancer


name: Qualitative, next-generation DNA sequencing detection of single-nucleotide variants and deletions in EGFR and KRAS genes in formalin-fixed paraffin-embedded (FFPE) solid tumor samples, reported as presence or absence of targeted mutation(s), with recommended therapeutic options in lung cancer


name: Carrier screening for severe inherited conditions (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia), regardless of race or self-identified ancestry, genomic sequence analysis panel, must include analysis of 5 genes (CFTR, SMN1, HBB, HBA1, HBA2)


name: Genomic sequence analysis panel that must include analysis of 5 genes (CFTR, SMN1, HBB, HBA1, HBA2) as a carrier screening for severe inherited conditions such as cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies, alpha thalassemia, regardless of race or self-identified ancestry


name: Genomic sequence analysis panel, carrier screening for severe inherited conditions, must include analysis of 5 genes (CFTR, SMN1, HBB, HBA1, HBA2)


name: Test for monoclonal paraproteins in blood, results reported as a baseline presence or absence of detectable clonotypic peptides in multiple myeloma


name: Oncology (multiple myeloma), liquid chromatography with tandem mass spectrometry (LC-MS/MS), monoclonal paraprotein sequencing analysis, serum, results reported as baseline presence or absence of detectable clonotypic peptides


name: Oncology (multiple myeloma), LC-MS/MS, peptide ion quantification, serum, results compared with baseline to determine monoclonal paraprotein abundance


name: Testing paraproteins in blood, results compared to baseline results to determine monoclonal paraprotein abundance in multiple myeloma


name: Testing to detect methylated PENK DNA in urine, reported as likelihood of bladder cancer


name: Oncology (bladder), methylated PENK DNA detection by linear target enrichment-quantitative methylation-specific real-time PCR (LTE-qMSP), urine, reported as likelihood of bladder cancer


name: Oncology (colorectal cancer), cell-free DNA (cfDNA), methylation-based quantitative PCR assay (SEPTIN9, IKZF1, BCAT1, Septin9-2, VAV3, BCAN), plasma, reported as presence or absence of circulating tumor DNA (ctDNA)


name: Testing for cell-free DNA in plasma, reported as the presence or absence of circulating tumor DNA in colorectal cancer


name: Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping (0454U)


name: Testing by optical genome mapping for constitutional/heritable disorders


name: Optical genome mapping for identification of copy number variations, inversions, insertions, translocations, and other structural variants for constitutional/heritable disorders


name: Infectious agents (sexually transmitted infection), Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis, multiplex amplified probe technique, vaginal, endocervical, gynecological specimens, oropharyngeal swabs, rectal swabs, female or male urine, each pathogen reported as detected or not detected


name: Testing for sexually transmitted infections in vaginal, endocervical, gynecological specimens, oropharyngeal swabs, rectal swabs, or female or male urine, results reported as detected or not detected


name: Multiplex amplified probe technique for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in endocervical specimen, each pathogen reported as detected or not detected


name: Multiplex amplified probe technique for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in female urine, each pathogen reported as detected or not detected


name: Multiplex amplified probe technique for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in gynecological specimen, each pathogen reported as detected or not detected


name: Multiplex amplified probe technique for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in male urine, each pathogen reported as detected or not detected


name: Multiplex amplified probe technique for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in oropharyngeal swab, each pathogen reported as detected or not detected


name: Multiplex amplified probe technique for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in rectal swab, each pathogen reported as detected or not detected


name: Multiplex amplified probe technique for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in vaginal specimen, each pathogen reported as detected or not detected


name: Autoimmune (rheumatoid arthritis), next-generation sequencing (NGS), gene expression testing of 19 genes, whole blood, with analysis of anti-cyclic citrullinated peptides (CCP) levels, combined with sex, patient global assessment, and body mass index (BMI), algorithm reported as a score that predicts nonresponse to tumor necrosis factor inhibitor (TNFi) therapy


name: Gene expression testing of 19 genes in whole blood with inclusion of patient factors, result report as a risk score that predicts nonresponse to tumor necrosis factor inhibitor therapy in rheumatoid arthritis


name: Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 9 PFAS compounds by LC-MS/MS, plasma or serum, quantitative


name: Testing for 9 perfluoroalkyl compounds in plasma or serum


name: Quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) testing for 9 Perfluoroalkyl substance (PFAS) compounds in plasma


name: Quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) testing for 9 Perfluoroalkyl substance (PFAS) compounds in serum


name: Oncology (breast cancer), S100A8 and S100A9, by enzyme-linked immunosorbent assay (ELISA), tear fluid with age, algorithm reported as a risk score


name: Testing for S100A8 and S100A9 in tear fluid with age, reported as a risk score for breast cancer


name: β-amyloid (Abeta42) and total tau (tTau), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology


name: Testing for β-amyloid and total tau in spinal fluid, ratio reported as positive or negative for amyloid pathology


name: Oncology, whole blood or buccal, DNA single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, with variant analysis and reported phenotypes


name: DNA testing of 24 genes in whole blood or saliva in cancer


name: DNA single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, with variant analysis and reported phenotypes in whole blood, in cancer


name: DNA single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, with variant analysis and reported phenotypes in whole buccal swab, in cancer


name: Oncology, pharmacogenomic analysis of single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, whole blood or buccal swab, with variant analysis, including impacted gene-drug interactions and reported phenotypes


name: Analysis of 24 genes in whole blood or saliva for gene-drug interactions in cancer


name: Pharmacogenomic analysis of single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes in buccal swab, with variant analysis, including impacted gene-drug interactions and reported phenotypes in cancer


name: Pharmacogenomic analysis of single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes in whole blood, with variant analysis, including impacted gene-drug interactions and reported phenotypes in cancer


name: Melatonin levels test, sleep study, 7 or 9 sample melatonin profile (cortisol optional), enzyme-linked immunosorbent assay (ELISA), saliva, screening/preliminary


name: Screening testing of melatonin levels in saliva during sleep study


name: Oncology (cervix), mRNA gene expression profiling of 14 biomarkers (E6 and E7 of the highest-risk human papillomavirus [HPV] types 16, 18, 31, 33, 45, 52, 58), by real-time nucleic acid sequence-based amplification (NASBA), exo- or endocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker


name: Gene expression profiling of high-risk HPV types in cervical cells, reported as positive or negative for increased risk of abnormal cervical cells or cervical cancer for each type


name: mRNA gene expression by real-time nucleic acid sequence-based amplification (NASBA), profiling of 14 biomarkers (E6 and E7 of the highest-risk human papillomavirus [HPV] types 16, 18, 31, 33, 45, 52, 58) in endocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker


name: mRNA gene expression by real-time nucleic acid sequence-based amplification (NASBA), profiling of 14 biomarkers (E6 and E7 of the highest-risk human papillomavirus [HPV] types 16, 18, 31, 33, 45, 52, 58) in exocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker


name: Screening test for DNA markers in stool reported as a positive or negative result for colorectal cancer


name: Oncology (colorectal) screening, quantitative real-time target and signal amplification, methylated DNA markers, including LASS4, LRRC4 and PPP2R5C, a reference marker ZDHHC1, and a protein marker (fecal hemoglobin), utilizing stool, algorithm reported as a positive or negative result


name: Oncology (urothelial carcinoma), DNA, quantitative methylation-specific PCR of 2 genes (ONECUT2, VIM), algorithmic analysis reported as positive or negative


name: DNA testing for 2 genes reported as a positive or negative result for bladder cancer


name: Cardiology (coronary artery disease [CAD]), DNA, genome-wide association studies (564856 single-nucleotide polymorphisms [SNPs], targeted variant genotyping), patient lifestyle and clinical data, buccal swab, algorithm reported as polygenic risk to acquired heart disease


name: DNA genome study with patient lifestyle and clinical data, using saliva, results reported as a risk for heart disease


name: DNA genome-wide association studies (564856 single-nucleotide polymorphisms [SNPs], targeted variant genotyping), patient lifestyle and clinical data, buccal swab, algorithm reported as polygenic risk to acquired heart disease


name: Oncology (bladder), DNA, next-generation sequencing (NGS) of 60 genes and whole genome aneuploidy, urine, algorithms reported as minimal residual disease (MRD) status positive or negative and quantitative disease burden


name: DNA sequencing of 60 genes in urine, results reported as minimal residual disuse positive or negative and disease burden


name: Hepatology (nonalcoholic steatohepatitis [NASH]), miR-34a-5p, alpha 2-macroglobulin, YKL40, HbA1c, serum and whole blood, algorithm reported as a single score for NASH activity and fibrosis


name: Testing in serum and whole blood reported as a single score for nonalcoholic steatohepatitis and fibrosis


name: Testing for miR-34a-5p, alpha 2-macroglobulin, YKL40, HbA1c in serum, algorithm reported as a single score for nonalcoholic steatohepatitis (NASH) activity and fibrosis


name: Testing for miR-34a-5p, alpha 2-macroglobulin, YKL40, HbA1c in whole blood, algorithm reported as a single score for nonalcoholic steatohepatitis (NASH) activity and fibrosis


name: Rare diseases (constitutional/heritable disorders), whole genome sequence analysis for chromosomal abnormalities, copy number variants, duplications/deletions, inversions, unbalanced translocations, regions of homozygosity (ROH), inheritance pattern that indicate uniparental disomy (UPD), and aneuploidy, fetal sample (amniotic fluid, chorionic villus sample, or products of conception), identification and categorization of genetic variants, diagnostic report of fetal results based on phenotype with maternal sample and paternal sample, if performed, as comparators and/or maternal cell contamination


name: Whole genome sequencing in amniotic fluid, chorionic villus sample, or products of conception, results reported based on phenotype for constitutional/heritable disorders


name: Whole genome sequence analysis for chromosomal abnormalities, copy number variants, duplications/deletions, inversions, unbalanced translocations, regions of homozygosity (ROH), inheritance pattern that indicate uniparental disomy (UPD), and aneuploidy in amniotic fluid, with identification and categorization of genetic variants, diagnostic report of fetal results based on phenotype with maternal sample and paternal sample, if performed, as comparators and/or maternal cell contamination for constitutional/heritable disorders


name: Whole genome sequence analysis for chromosomal abnormalities, copy number variants, duplications/deletions, inversions, unbalanced translocations, regions of homozygosity (ROH), inheritance pattern that indicate uniparental disomy (UPD), and aneuploidy in chorionic villus sample, with identification and categorization of genetic variants, diagnostic report of fetal results based on phenotype with maternal sample and paternal sample, if performed, as comparators and/or maternal cell contamination for constitutional/heritable disorders


name: Whole genome sequence analysis for chromosomal abnormalities, copy number variants, duplications/deletions, inversions, unbalanced translocations, regions of homozygosity (ROH), inheritance pattern that indicate uniparental disomy (UPD), and aneuploidy in products of conception, with identification and categorization of genetic variants, diagnostic report of fetal results based on phenotype with maternal sample and paternal sample, if performed, as comparators and/or maternal cell contamination for constitutional/heritable disorders


name: Oncology (oropharyngeal), detection of minimal residual disease by next-generation sequencing (NGS) based quantitative evaluation of 8 DNA targets, cell-free HPV 16 and 18 DNA from plasma


name: Next-generation sequencing of 8 DNA targets in plasma for detection of minimal residual disease in head and neck cancer


name: Testing for 35 variants of KRAS and NRAS genes in tissue sample, reported as predictive identification of detected mutations in colorectal cancer


name: Oncology (colorectal cancer), qualitative real-time PCR of 35 variants of KRAS and NRAS genes (exons 2, 3, 4), formalin-fixed paraffin-embedded (FFPE), predictive, identification of detected mutations


name: Carbonic anhydrase VI (CA VI), parotid specific/secretory protein (PSP) and salivary protein (SP1) IgG, IgM, and IgA antibodies, enzyme-linked immunosorbent assay (ELISA), semiqualitative, blood, reported as predictive evidence of early Sjögren's syndrome


name: Testing for proteins and antibodies in blood reported as predictive evidence of early Sjögren syndrome


name: Oncology (solid tumor), next-generation sequencing (NGS) of DNA from formalin-fixed paraffin-embedded (FFPE) tissue with comparative sequence analysis from a matched normal specimen (blood or saliva), 648 genes, interrogation for sequence variants, insertion and deletion alterations, copy number variants, rearrangements, microsatellite instability, and tumor-mutation burden


name: Next-generation sequencing of DNA from tissue sample of 648 genes with comparative sequence analysis from a matched normal blood or saliva specimen in solid tumor cancer


name: Hereditary pan-cancer (eg, hereditary sarcomas, hereditary endocrine tumors, hereditary neuroendocrine tumors, hereditary cutaneous melanoma), genomic sequence analysis panel of 88 genes with 20 duplications/deletions using next-generation sequencing (NGS), Sanger sequencing, blood or saliva, reported as positive or negative for germline variants, each gene


name: Next-generation sequencing of 88 genes in blood or saliva, results reported as positive or negative for variants of each gene for hereditary cancers


name: Genomic sequence analysis panel of 88 genes with 20 duplications/deletions using next-generation sequencing (NGS), Sanger sequencing in whole blood, reported as positive or negative for germline variants for each gene in hereditary pan-cancer


name: Hereditary prostate cancer-related disorders, genomic sequence analysis panel using next-generation sequencing (NGS), Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA), and array comparative genomic hybridization (CGH), evaluation of 23 genes and duplications/deletions when indicated, pathologic mutations reported with a genetic risk score for prostate cancer


name: Next-generation sequencing of 23 genes reported as pathologic mutations with a genetic risk score for prostate cancer


name: Genomic sequence analysis panel using next-generation sequencing (NGS), Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA), and array comparative genomic hybridization (CGH), evaluation of 23 genes and duplications/deletions when indicated, pathologic mutations reported with a genetic risk score for prostate cancer


name: Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis and reported phenotypes


name: Pharmacogenomic genotyping of 14 genes including reported phenotypes to evaluate drug metabolism in psychiatric disorders


name: Drug metabolism and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis and reported phenotypes in buccal swab for psychiatric disorders


name: Drug metabolism and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis and reported phenotypes in whole blood for psychiatric disorders


name: Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis, including impacted gene-drug interactions and reported phenotypes


name: Pharmacogenomic genotyping of 14 genes including gene-drug interactions and reported phenotypes to evaluate drug metabolism in psychiatric disorders


name: Drug metabolism and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis, including impacted gene-drug interactions and reported phenotypes in buccal swab for psychiatric disorders


name: Drug metabolism and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis, including impacted gene-drug interactions and reported phenotypes in whole blood for psychiatric disorders


name: Oncology (non-small cell lung cancer), DNA and RNA, digital PCR analysis of 9 genes (EGFR, KRAS, BRAF, ALK, ROS1, RET, NTRK 1/2/3, ERBB2, and MET) in formalin-fixed paraffin-embedded (FFPE) tissue, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements, and reported as actionable detected variants for therapy selection


name: DNA and RNA analysis of 9 genes to determine therapy selection in non-small cell lung cancer


name: Digital PCR DNA analysis of 9 genes (EGFR, KRAS, BRAF, ALK, ROS1, RET, NTRK 1/2/3, ERBB2, and MET), interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements in formalin-fixed paraffin-embedded (FFPE) tissue. reported as actionable detected variants for therapy selection in non-small cell lung cancer


name: Digital PCR RNA analysis of 9 genes (EGFR, KRAS, BRAF, ALK, ROS1, RET, NTRK 1/2/3, ERBB2, and MET), interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements in formalin-fixed paraffin-embedded (FFPE) tissue. reported as actionable detected variants for therapy selection in non-small cell lung cancer


name: Infectious disease (bacteria, viruses, fungi, and parasites), cerebrospinal fluid (CSF), metagenomic next-generation sequencing (DNA and RNA), bioinformatic analysis, with positive pathogen identification


name: DNA and RNA next generation sequencing for identifying pathogens in bacteria, virus, fungal, an parasite infection


name: Metagenomic next-generation DNA sequencing in cerebrospinal fluid (CSF) bioinformatic analysis, with positive pathogen identification in infectious disease


name: Metagenomic next-generation RNA sequencing in cerebrospinal fluid (CSF) bioinformatic analysis, with positive pathogen identification in infectious disease


name: IDH1 (isocitrate dehydrogenase 1 [NADP+]), IDH2 (isocitrate dehydrogenase 2 [NADP+]), and TERT (telomerase reverse transcriptase) promoter (eg, central nervous system [CNS] tumors), next-generation sequencing (single-nucleotide variants [SNV], deletions, and insertions)


name: Next-generation sequencing of genes in central nervous system tumors


name: Obstetrics (preeclampsia), biochemical assay of soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF), serum, ratio reported for sFlt-1/PlGF, with risk of progression for preeclampsia with severe features within 2 weeks


name: Testing of specific protein and factors to determine risk of progression of preeclampsia


name: Infectious disease (Neisseria gonorrhoeae), sensitivity, ciprofloxacin resistance (gyrA S91F point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of fluoroquinolone resistance


name: Testing for probability of fluoroquinolone resistance in gonorrhea


name: Testing for Neisseria gonorrhoeae, ciprofloxacin resistance (gyrA S91F point mutation) in oral swab, algorithm reported as probability of fluoroquinolone resistance


name: Testing for Neisseria gonorrhoeae, ciprofloxacin resistance (gyrA S91F point mutation) in rectal swab, algorithm reported as probability of fluoroquinolone resistance


name: Testing for Neisseria gonorrhoeae, ciprofloxacin resistance (gyrA S91F point mutation) in vaginal swab, algorithm reported as probability of fluoroquinolone resistance


name: Infectious disease (Mycoplasma genitalium), macrolide sensitivity (23S rRNA point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of macrolide resistance


name: Testing for probability of macrolide resistance in in mycoplasma genitalium


name: Testing for Mycoplasma genitalium macrolide sensitivity (23S rRNA point mutation) in oral swab, algorithm reported as probability of macrolide resistance


name: Testing for Mycoplasma genitalium macrolide sensitivity (23S rRNA point mutation) in rectal swab, algorithm reported as probability of macrolide resistance


name: Testing for Mycoplasma genitalium macrolide sensitivity (23S rRNA point mutation) in vaginal swab, algorithm reported as probability of macrolide resistance


name: Oncology (solid tumor), cell-free DNA and RNA by next-generation sequencing, interpretative report for germline mutations, clonal hematopoiesis of indeterminate potential, and tumor-derived single-nucleotide variants, small insertions/deletions, copy number alterations, fusions, microsatellite instability, and tumor mutational burden


name: RNA next-generation sequencing in solid tumor cancer


name: Cell-free DNA by next-generation sequencing, interpretative report for germline mutations, clonal hematopoiesis of indeterminate potential, and tumor-derived single-nucleotide variants, small insertions/deletions, copy number alterations, fusions, microsatellite instability, and tumor mutational burden in solid tumor cancer


name: Cell-free RNA by next-generation sequencing, interpretative report for germline mutations, clonal hematopoiesis of indeterminate potential, and tumor-derived single-nucleotide variants, small insertions/deletions, copy number alterations, fusions, microsatellite instability, and tumor mutational burden in solid tumor cancer


name: Oncology (pan-solid tumor), next-generation sequencing analysis of tumor methylation markers present in cell-free circulating tumor DNA, algorithm reported as quantitative measurement of methylation as a correlate of tumor fraction


name: DNA next-generation sequencing of tumor methylation markers present in cell-free circulating tumor DNA in pan-solid tumor


name: Next-generation sequencing analysis of tumor methylation markers present in cell-free circulating tumor DNA, algorithm reported as quantitative measurement of methylation as a correlate of tumor fraction in solid tumor cancer


name: Oncology (solid tumor), cell-free circulating DNA, targeted genomic sequence analysis panel of 84 genes, interrogation for sequence variants, aneuploidy-corrected gene copy number amplifications and losses, gene rearrangements, and microsatellite instability


name: Genomic sequence analysis of 84 genes in solid tumors


name: Obstetrics (fetal antigen noninvasive prenatal test), cell-free DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized pregnancies, reported as selected antigen(s) detected or not detected


name: DNA sequence analysis for detection of fetal presence of antigen(s)


name: Cell-free DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized pregnancies, reported as selected antigen(s) detected or not detected


name: Obstetrics (single-gene noninvasive prenatal test), cell-free DNA sequence analysis of 1 or more targets (eg, CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation-dosage analysis based on molecular counts to determine fetal inheritance of maternal mutation, algorithm reported as a fetal risk score for the condition (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia)


name: Single-gene noninvasive prenatal test to determine fetal risk score for inherited conditions


name: Cell-free DNA sequence analysis of 1 or more targets (eg, CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation-dosage analysis based on molecular counts to determine fetal inheritance of maternal mutation, algorithm reported as a fetal risk score for the condition


name: Oncology (cutaneous or uveal melanoma), circulating tumor cell selection, morphological characterization and enumeration based on differential CD146, high molecular-weight melanoma-associated antigen, CD34 and CD45 protein biomarkers, peripheral blood


name: Testing for antigen and protein biomarkers in melanoma(s)


name: Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of estrogen receptor (ER) protein biomarker-expressing cells, peripheral blood


name: Testing for protein biomarkers and quantification of estrogen receptor protein biomarker expressing cells in solid tumors


name: Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of PD-L1 protein biomarker-expressing cells, peripheral blood


name: Testing for protein biomarkers and quantification of PD-L1 protein biomarker expressing cells in solid tumors


name: Transplantation medicine, quantification of donor-derived cell-free DNA (cfDNA) using next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA


name: Testing of donor-derived cell-free DNA, reported as percentage of donor-derived cell-free DNA to inform likelihood of organ rejection


name: Red blood cell antigen (fetal RhD gene analysis), next-generation sequencing of circulating cell-free DNA (cfDNA) of blood in pregnant individuals known to be RhD negative, reported as positive or negative


name: Red blood cell antigen testing in pregnant individuals known to be RhD negative


name: Quantification of donor-derived cell-free DNA (cfDNA) using next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA for fetal RhD gene analysis


name: Oncology (prostate), analysis of circulating plasma proteins (tPSA, fPSA, KLK2, PSP94, and GDF15), germline polygenic risk score (60 variants), clinical information (age, family history of prostate cancer, prior negative prostate biopsy), algorithm reported as risk of likelihood of detecting clinically significant prostate cancer


name: Analysis of proteins to determine risk of clinically significant prostate cancer


name: Oncology (colorectal), cell-free DNA, 8 genes for mutations, 7 genes for methylation by real-time RT-PCR, and 4 proteins by enzyme-linked immunosorbent assay, blood, reported positive or negative for colorectal cancer or advanced adenoma risk


name: Analysis of genes and proteins to determine risk of colorectal cancer or advanced adenoma risk


name: Oncology (prostate), mRNA gene-expression profiling by real-time RT-PCR of 6 genes (FOXM1, MCM3, MTUS1, TTC21B, ALAS1, and PPP2CA), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a risk score for prostate cancer


name: mRNA gene-expression profiling of 6 genes to determine risk for prostate cancer


name: Oncology (colorectal), next-generation sequencing for mutation detection in 43 genes and methylation pattern in 45 genes, blood, and formalin-fixed paraffin-embedded (FFPE) tissue, report of variants and methylation pattern with interpretation


name: Next-generation sequencing for mutation detection in 43 genes and methylation pattern in 45 genes in colorectal cancer


name: Next-generation sequencing for mutation detection in 43 genes and methylation pattern in 45 genes in blood, report of variants and methylation pattern with interpretation in colorectal cancer


name: Next-generation sequencing for mutation detection in 43 genes and methylation pattern in 45 genes in formalin-fixed paraffin-embedded (FFPE) tissue, report of variants and methylation pattern with interpretation in colorectal cancer


name: Oncology (colorectal and lung), DNA from formalin-fixed paraffin-embedded (FFPE) tissue, next-generation sequencing of 8 genes (NRAS, EGFR, CTNNB1, PIK3CA, APC, BRAF, KRAS, and TP53), mutation detection


name: Next-generation sequencing for mutation detection in 8 genes in colorectal cancer and lung cancer


name: Next-generation- DNA sequencing of 8 genes (NRAS, EGFR, CTNNB1, PIK3CA, APC, BRAF, KRAS, and TP53), mutation detection from formalin-fixed paraffin-embedded (FFPE) tissue in colorectal cancer


name: Next-generation- DNA sequencing of 8 genes (NRAS, EGFR, CTNNB1, PIK3CA, APC, BRAF, KRAS, and TP53), mutation detection from formalin-fixed paraffin-embedded (FFPE) tissue in lung cancer


name: Autoinflammatory disease (VEXAS syndrome), DNA, UBA1 gene mutations, targeted variant analysis (M41T, M41V, M41L, c.118-2A>C, c.118-1G>C, c.118-9_118-2del, S56F, S621C)


name: Testing for gene mutations in VEXAS syndrome


name: Oncology (colorectal), blood, quantitative measurement of cell-free DNA (cfDNA)


name: Measurement of cell-free DNA in colorectal cancer


name: Human papillomavirus (HPV), E6/E7 markers for high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), cervical cells, branched-chain capture hybridization, reported as negative or positive for high risk for HPV


name: Testing for high-risk markers in human papillomavirus


name: Neurology (Alzheimer disease), beta amyloid (Aβ40, Aβ42, Aβ42/40 ratio) and tau-protein (ptau217, np-tau217, ptau217/np-tau217 ratio), blood, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS), algorithm score reported as likelihood of positive or negative for amyloid plaques


name: Testing for beta-amyloid and tau-protein to determine likelihood for amyloid plaques in Alzheimer disease


name: Testing for detection of 17 pathologic organism for urinary tract infection


name: Infectious disease (urinary tract infection), identification of 17 pathologic organisms, urine, real-time PCR, reported as positive or negative for each organism


name: Infectious disease (vaginal infection), identification of 32 pathogenic organisms, swab, real-time PCR, reported as positive or negative for each organism


name: Detection of 32 pathogenic organisms in vaginal infection


name: Gastroenterology (Barrett's esophagus), esophageal cells, DNA methylation analysis by next-generation sequencing of at least 89 differentially methylated genomic regions, algorithm reported as likelihood for Barrett's esophagus


name: Next-generation sequencing of at least 89 genomic regions to determine likelihood of Barrett's esophagus


name: Oncology (ovarian), DNA, whole-genome sequencing with 5-hydroxymethylcytosine (5hmC) enrichment, using whole blood or plasma, algorithm reported as cancer detected or not detected


name: Whole-genome DNA sequencing for detection of ovarian cancer


name: Whole-genome DNA sequencing with 5-hydroxymethylcytosine (5hmC) enrichment, using plasma, algorithm reported as cancer detected or not detected in ovarian cancer


name: Whole-genome DNA sequencing with 5-hydroxymethylcytosine (5hmC) enrichment, using whole blood, algorithm reported as cancer detected or not detected in ovarian cancer


name: Transplantation medicine, quantification of donor-derived cell-free DNA using 40 single-nucleotide polymorphisms (SNPs), plasma, and urine, initial evaluation reported as percentage of donor-derived cell-free DNA with risk for active rejection


name: Testing for quantification of donor-derived cell-free DNA using 40 single-nucleotide polymorphisms to determine risk for active transplant rejection


name: Quantification of donor-derived cell-free DNA using 40 single-nucleotide polymorphisms (SNPs) in plasma, initial evaluation reported as percentage of donor-derived cell-free DNA with risk for active rejection in transplantation medicine


name: Quantification of donor-derived cell-free DNA using 40 single-nucleotide polymorphisms (SNPs) in urine, initial evaluation reported as percentage of donor-derived cell-free DNA with risk for active rejection in transplantation medicine


name: Transplantation medicine, quantification of donor-derived cell-free DNA using up to 12 single-nucleotide polymorphisms (SNPs) previously identified, plasma, reported as percentage of donor-derived cell-free DNA with risk for active rejection


name: Testing for quantification of donor-derived cell-free DNA using up to 12 single-nucleotide polymorphisms to determine risk for active transplant rejection


name: Oncology (pancreatic cancer), augmentative algorithmic analysis of 16 genes from previously sequenced RNA whole-transcriptome data, reported as probability of predicted molecular subtype


name: Augmentative algorithmic analysis of 16 genes using previously sequenced RNA data to determine probability of predicted molecular subtype in pancreatic cancer


name: Oncology (solid tumor), tumor cell culture in 3D microenvironment, 36 or more drug panel, reported as tumor-response prediction for each drug


name: Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) status, formalin-fixed paraffin-embedded (FFPE) tissue, reported as increased or decreased probability of MSI-high (MSI-H)


name: Augmentative algorithmic analysis of digitized whole-slide imaging of tissue features in prostate cancer


name: Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) and homologous recombination deficiency (HRD) status, formalin-fixed paraffin-embedded (FFPE) tissue, reported as increased or decreased probability of each biomarker


name: Augmentative algorithmic analysis of digitized whole-slide imaging of tissue features reported as increased or decreased probability of each biomarker in prostate cancer


name: Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of adalimumab (ADL) levels in venous serum in patients undergoing adalimumab therapy, results reported as a numerical value as micrograms per milliliter (µg/mL)


name: Testing for adalimumab levels in patients undergoing adalimumab therapy for irritable bowel disease


name: Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of infliximab (IFX) levels in venous serum in patients undergoing infliximab therapy, results reported as a numerical value as micrograms per milliliter (µg/mL)


name: Testing for infliximab patients undergoing infliximab therapy for irritable bowel disease


name: Drug metabolism, whole blood, pharmacogenomic genotyping of 40 genes and CYP2D6 copy number variant analysis, reported as metabolizer status


name: Pharmacogenomic genotyping of 40 genes reported as metabolizer status for drug metabolism


name: Therapeutic drug monitoring, 80 or more psychoactive drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally and maximally effective dose of prescribed and non-prescribed medications


name: Testing for 80 or more psychoactive drugs or substances, minimally and maximally effective dose of prescribed and non-prescribed medications


name: Liquid chromatography with tandem mass spectrometry (LC-MS/MS) of 80 or more psychoactive drugs or substances in plasma, qualitative and quantitative therapeutic minimally and maximally effective dose of prescribed and non-prescribed medications


name: Therapeutic drug monitoring, 90 or more pain and mental health drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications


name: Testing for 90 or more pain and mental health drugs or substances, minimally effective range of prescribed and non-prescribed medications


name: Therapeutic drug monitoring, medications specific to pain, depression, and anxiety, LC-MS/MS, plasma, 110 or more drugs or substances, qualitative and quantitative therapeutic minimally effective range of prescribed, non-prescribed, and illicit medications in circulation


name: Testing for 110 or more medications for pain, depression, and anxiety, minimally effective range of prescribed, non-prescribed medications, and illicit medications


name: Liquid chromatography with tandem mass spectrometry (LC-MS/MS) of 110 or more drugs or substances in plasma, qualitative and quantitative therapeutic minimally effective range of prescribed, non-prescribed, and illicit medications in circulation


name: Therapeutic drug monitoring, 200 or more drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications


name: Testing for 200 or more drugs or substances, minimally effective range of prescribed and non-prescribed medications


name: Liquid chromatography with tandem mass spectrometry (LC-MS/MS) o 200 or more drugs or substances in plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications


name: Influenza vaccine, trivalent, derived from cell cultures, antibiotic free, 0.5 mL dosage, for intramuscular use


name: Influenza virus vaccine, H5N8, derived from cell cultures, adjuvanted, for intramuscular use


name: Pneumococcal conjugate vaccine, 21 valent (PCV21), for intramuscular use


name: Influenza virus vaccine, quadrivalent (qIRV), mRNA


name: Influenza virus vaccine, quadrivalent (qIRV), mRNA; 30 mcg/0.5 mL dosage, for intramuscular use


name: Influenza virus vaccine, quadrivalent (qIRV), mRNA; 60 mcg/0.5 mL dosage, for intramuscular use


name: Meningococcal pentavalent vaccine, Men B-4C recombinant proteins and outer membrane vesicle and conjugated Men A, C, W, Y-diphtheria toxoid carrier, for intramuscular use


name: Bilateral computerized ophthalmic diagnostic imaging of anterior segment with interpretation and report


name: Bilateral optical coherence tomography (OCT) of anterior segment with interpretation and report


name: Unilateral computerized ophthalmic diagnostic imaging of anterior segment with interpretation and report


name: Unilateral optical coherence tomography (OCT) of anterior segment with interpretation and report


name: Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral


name: Bilateral computerized ophthalmic diagnostic imaging of optic nerve with interpretation and report


name: Bilateral optical coherence tomography (OCT) of optic nerve with interpretation and report


name: Unilateral computerized ophthalmic diagnostic imaging of optic nerve with interpretation and report


name: Unilateral optical coherence tomography (OCT) of optic nerve with interpretation and report


name: Bilateral computerized ophthalmic diagnostic imaging of retina with interpretation and report


name: Bilateral optical coherence tomography (OCT) of retina with interpretation and report


name: Unilateral computerized ophthalmic diagnostic imaging of retina with interpretation and report


name: Unilateral optical coherence tomography (OCT) of retina with interpretation and report


name: Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina, including OCT angiography


name: Imaging of retina with optical coherence tomography angiography


name: Bilateral computerized ophthalmic diagnostic imaging of retina, with OCT angiography, with interpretation and report


name: Bilateral optical coherence tomography (OCT) of retina with, with OCT angiography, interpretation and report


name: Unilateral computerized ophthalmic diagnostic imaging of retina, with OCT angiography, with interpretation and report


name: Unilateral optical coherence tomography (OCT) of retina with, with OCT angiography, interpretation and report


name: Comprehensive electrophysiologic evaluation with transseptal catheterizations, with insertion and repositioning of transseptal electrode catheters, with induction of arrhythmia, right atrial and left ventricular pacing and recording, and intracardiac catheter ablation of atrial fibrillation by pulmonary vein isolation


name: Ultrasound of blood flow within brain for atypical blood flow detection with microbubble injection


name: Vasoreactivity study performed with transcranial Doppler study of intracranial arteries, complete (List separately in addition to code for primary procedure)


name: Ultrasound of blood flow withing brain to assess flexibility of vessels


name: Emboli detection without intravenous microbubble injection performed with transcranial Doppler study of intracranial arteries, complete (List separately in addition to code for primary procedure)


name: Ultrasound of vessels in brain for detection of blood clots


name: Venous-arterial shunt detection with intravenous microbubble injection performed with transcranial Doppler study of intracranial arteries, complete (List separately in addition to code for primary procedure)


name: Detection of abnormal blood flow in brain vessels using ultrasound with microbubble injection


name: Medical genetics and genetic counseling services, each 30 minutes of total time provided by the genetic counselor on the date of the encounter


name: Counseling for genetic testing provided by a genetic counselor, each 30 minutes of total time on the date of encounter


name: Treatment of behavior impacting health in group setting, each additional 15 minutes


name: Administration of seasonal dose by intramuscular injection, with counseling by physician or other qualified health care professional


name: Acupuncture with insertion of 1 or more needles, each additional 15 minutes of personal one-on-one contact with the patient


name: Acupuncture with electrical stimulation and insertion of 1 or more needles, each additional 15 minutes of personal one-on-one contact with the patient


name: Non-Face-to-Face Nonphysician Qualified Health Care Professional Services


name: Telephone discussion provided to an established patient by nonphysician professional, 5-10 minutes


name: Telephone assessment and management service provided to an established patient, parent, or guardian by a nonphysician qualified health care professional, 5-10 minutes of medical discussion


name: Telephone discussion provided to an established patient by nonphysician professional, 11-20 minutes


name: Telephone assessment and management service provided to an established patient, parent, or guardian by a nonphysician qualified health care professional, 11-20 minutes of medical discussion


name: Telephone discussion provided to an established patient by nonphysician professional, 21-30 minutes


name: Telephone assessment and management service provided to an established patient, parent, or guardian by a nonphysician qualified health care professional, 21-30 minutes of medical discussion


name: Online digital evaluation and management service provided to an established patient by nonphysician professional for up to 7 days, total time 5-10 minutes


name: Online digital evaluation and management service provided to an established patient by nonphysician professional for up to 7 days, total time 11-20 minutes


name: Remote therapeutic monitoring (eg, therapy adherence, therapy response, digital therapeutic intervention)


name: Set-up and patient education on use of equipment for remote therapeutic monitoring


name: Initial set-up and patient education on use of equipment for remote therapeutic monitoring of digital therapeutic intervention


name: Initial set-up and patient education on use of equipment for remote therapeutic monitoring of therapy adherence


name: Initial set-up and patient education on use of equipment for remote therapeutic monitoring of therapy response


name: Device supply for data access or data transmissions to support monitoring of respiratory system, each 30 days


name: Device supply with daily recording and programmed alert transmission for remote therapeutic monitoring for digital therapeutic intervention for respiratory system, each 30 days


name: Device supply with daily recording and programmed alert transmission for remote therapeutic monitoring for therapy response of respiratory system, each 30 days


name: Device supply with daily recording and programmed alert transmission for remote therapeutic monitoring of therapy adherence for respiratory system, each 30 days


name: Device supply with daily recording for remote therapeutic monitoring for digital therapeutic intervention for respiratory system, each 30 days


name: Device supply with daily recording for remote therapeutic monitoring for therapy response of respiratory system, each 30 days


name: Device supply with daily recording for remote therapeutic monitoring of therapy adherence for respiratory system, each 30 days


name: Device supply with programmed alert transmission for remote therapeutic monitoring of digital therapeutic intervention for respiratory system, each 30 days


name: Device supply with programmed alert transmission for remote therapeutic monitoring of therapy adherence for respiratory system, each 30 days


name: Device supply with programmed alert transmission for remote therapeutic monitoring of therapy response of respiratory system, each 30 days


name: Device supply for data access or data transmissions to support monitoring of musculoskeletal system, each 30 days


name: Device supply with daily recording and programmed alert transmission for remote therapeutic monitoring for digital therapeutic intervention for musculoskeletal system, each 30 days


name: Device supply with daily recording and programmed alert transmission for remote therapeutic monitoring for therapy response of musculoskeletal system, each 30 days


name: Device supply with daily recording and programmed alert transmission for remote therapeutic monitoring of therapy adherence for musculoskeletal system, each 30 days


name: Device supply with daily recording for remote therapeutic monitoring for digital therapeutic intervention for musculoskeletal system, each 30 days


name: Device supply with daily recording for remote therapeutic monitoring for therapy response of musculoskeletal system, each 30 days


name: Device supply with daily recording for remote therapeutic monitoring of therapy adherence for musculoskeletal system, each 30 days


name: Device supply with programmed alert transmission for remote therapeutic monitoring of digital therapeutic intervention for musculoskeletal system, each 30 days


name: Device supply with programmed alert transmission for remote therapeutic monitoring of therapy adherence for musculoskeletal system, each 30 days


name: Device supply with programmed alert transmission for remote therapeutic monitoring of therapy response of musculoskeletal system, each 30 days


name: Device supply for data access or data transmissions to support monitoring of cognitive behavioral therapy, each 30 days


name: Device supply with daily recording and programmed alert transmission for remote therapeutic monitoring for digital therapeutic intervention for cognitive behavioral therapy, each 30 days


name: Device supply with daily recording and programmed alert transmission for remote therapeutic monitoring for therapy response of cognitive behavioral therapy, each 30 days


name: Device supply with daily recording and programmed alert transmission for remote therapeutic monitoring of therapy adherence for cognitive behavioral therapy, each 30 days


name: Device supply with daily recording for remote therapeutic monitoring for digital therapeutic intervention for cognitive behavioral therapy, each 30 days


name: Device supply with daily recording for remote therapeutic monitoring for therapy response of cognitive behavioral therapy, each 30 days


name: Device supply with daily recording for remote therapeutic monitoring of therapy adherence for cognitive behavioral therapy, each 30 days


name: Device supply with programmed alert transmission for remote therapeutic monitoring of digital therapeutic intervention for cognitive behavioral therapy, each 30 days


name: Device supply with programmed alert transmission for remote therapeutic monitoring of therapy adherence for cognitive behavioral therapy, each 30 days


name: Device supply with programmed alert transmission for remote therapeutic monitoring of therapy response of cognitive behavioral therapy, each 30 days


name: Placement of bone marrow sampling port, including imaging guidance when performed


name: Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance


name: Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50 mL


name: Transperineal laser destruction of benign prostatic enlargement using imaging guidance for prostate volume greater than or equal to 50 mL


name: Automated eye-movement analysis with interpretation and report


name: High-resolution gastric electrophysiology mapping with simultaneous patient-symptom profiling, with interpretation and report


name: Injection(s), bone-substitute material for bone and/or soft tissue hardware fixation augmentation, including intraoperative imaging guidance, when performed


name: Injection(s) of bone-substitute material for bone and/or soft tissue hardware fixation augmentation, including intraoperative imaging guidance


name: Implantation of subcutaneous peritoneal ascites pump system, percutaneous, including pump-pocket creation, insertion of tunneled indwelling bladder and peritoneal catheters with pump connections, including all imaging and initial programming, when performed


name: Implantation of subcutaneous peritoneal ascites pump system through the skin, including pump-pocket creation, insertion of tunneled indwelling bladder and peritoneal catheters with pump connections, including all imaging and initial programming


name: Replacement of indwelling bladder and peritoneal catheters, including tunneling of catheter(s) and connection with previously implanted peritoneal ascites pump, including imaging and programming, when performed


name: Replacement of permanent bladder and peritoneal catheters, including tunneling of catheter(s) and connection with previously implanted peritoneal ascites pump, including imaging and programming, when performed


name: Revision of a subcutaneously implanted peritoneal ascites pump system, any component (ascites pump, associated peritoneal catheter, associated bladder catheter), including imaging and programming, when performed


name: Removal of a peritoneal ascites pump system, including implanted peritoneal ascites pump and indwelling bladder and peritoneal catheters


name: Removal of a peritoneal ascites pump system, including implanted peritoneal ascites pump and permanent bladder and peritoneal catheters


name: Programming of subcutaneously implanted peritoneal ascites pump system by physician or other qualified health care professional


name: Duplex scan of hemodialysis fistula, computer-aided, limited (volume flow, diameter, and depth, including only body of fistula)


name: Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease


name: Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging


name: Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structure


name: Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmission


name: Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and report


name: Cryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance to treatment, and removal of the oral device


name: Intraoperative therapeutic electrical stimulation of peripheral nerve to promote nerve regeneration, including lead placement and removal, upper extremity, minimum of 10 minutes


name: Intraoperative therapeutic electrical stimulation of peripheral nerve to promote nerve regeneration, including lead placement and removal, upper extremity, minimum of 10 minutes; initial nerve (List separately in addition to code for primary procedure)


name: Intraoperative therapeutic electrical stimulation of peripheral nerve to promote nerve regeneration, including lead placement and removal, upper extremity, minimum of 10 minutes; each additional nerve (List separately in addition to code for primary procedure)


name: Esophagoscopy, flexible, transoral, with initial transendoscopic mechanical dilation (eg, nondrug-coated balloon) followed by therapeutic drug delivery by drug-coated balloon catheter for esophageal stricture, including fluoroscopic guidance, when performed


name: Colonoscopy, flexible, with initial transendoscopic mechanical dilation (eg, nondrug-coated balloon) followed by therapeutic drug delivery by drug-coated balloon catheter for colonic stricture, including fluoroscopic guidance, when performed


name: Sigmoidoscopy, flexible, with initial transendoscopic mechanical dilation (eg, nondrug-coated balloon) followed by therapeutic drug delivery by drug-coated balloon catheter for colonic stricture, including fluoroscopic guidance, when performed


name: End-tidal control of inhaled anesthetic agents and oxygen to assist anesthesia care delivery (List separately in addition to code for primary procedure)


name: Non-thermal destruction via acoustic energy delivery to malignant renal tissue, including imaging guidance


name: Personalized target development for accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation derived from a structural and resting-state functional MRI, including data preparation and transmission, generation of the target, motor threshold-starting location, neuronavigation files and target report, review and interpretation


name: Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including target assessment, initial motor threshold determination, neuronavigation, delivery and management, initial treatment day


name: Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent treatment day


name: Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent motor threshold redetermination with delivery and management, per treatment day


name: Noninvasive assessment of blood oxygenation, gas exchange efficiency, and cardiorespiratory status, with physician or other qualified health care professional interpretation and report


name: Cannulation of the liver allograft in preparation for connection to the normothermic perfusion device and decannulation of the liver allograft following normothermic perfusion


name: Insertion of a tube into the liver allograft in preparation for connection to the normothermic perfusion device and removal of the tube from the liver allograft following normothermic perfusion


name: Connection of liver allograft to normothermic machine perfusion device, hemostasis control


name: Connection of liver allograft to normothermic machine perfusion device, hemostasis control; initial 4 hours of monitoring time, including hourly physiological and laboratory assessments (eg, perfusate temperature, perfusate pH, hemodynamic parameters, bile production, bile pH, bile glucose, biliary bicarbonate, lactate levels, macroscopic assessment)


name: Connection of liver allograft to normothermic machine perfusion device, blood clotting control; initial 4 hours of monitoring time, including hourly physiological and laboratory assessments


name: Connection of liver allograft to normothermic machine perfusion device, hemostasis control; each additional hour, including physiological and laboratory assessments (eg, perfusate temperature, perfusate pH, hemodynamic parameters, bile production, bile pH, bile glucose, biliary bicarbonate, lactate levels, macroscopic assessment) (List separately in addition to code for primary procedure)


name: Connection of liver allograft to normothermic machine perfusion device, blood clotting control; each additional hour, including physiological and laboratory assessments


name: Noninvasive augmentative arrhythmia analysis derived from quantitative computational cardiac arrhythmia simulations, based on selected intervals of interest from 12-lead electrocardiogram and uploaded clinical parameters, including uploading clinical parameters with interpretation and report